netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for VAC found 117 matches

Formulary items 52 matches
Sub Section Title / notes 34  matches
   
Open monograph to display formulary status BNF Category
  Absorbed Diptheria Low Dose, Tetanus, and Poliomyelitis VACcine Immunological products and vaccines - Diphtheria vaccines - 14.04
  Absorbed Diptheria Low Dose, Tetanus, Pertussis and Poliomyelitis VACcine Immunological products and vaccines - Diphtheria vaccines - 14.04
  Absorbed Diptheria, Tetanus, Pertussis and Poliomyelitis VACcine Immunological products and vaccines - Diphtheria vaccines - 14.04
  AVACopan  (Tavneos®) Musculoskeletal and joint diseases - Other drugs for rheumatic diseases - 10.01.05
  BCG VACcine
(Bacillus calmette-guerin VACcine) 		Immunological products and vaccines - BCG vaccines - 14.04
  BeVACizumab  (Avastin®) Malignant disease and immunosuppression - Bevacizumab - 08.01.05
  BeVACizumab 1.25mg/0.05ml intravitreal injection Eye - Subfoveal choroidal neovascularisation - 11.08.02
  BeVACizumab gamma  (Lytenava®) Eye - Subfoveal choroidal neovascularisation - 11.08.02
  BupiVACaine Hydrochloride Anaesthesia - Bupivacaine - 15.02
  COVID-19 VACcines Immunological products and vaccines - COVID-19 vaccine - 14.04
  DeucraVACitinib  (Sotyktu) Skin - Drugs affecting the immune response - 13.05.03
  Haemophilus Influenzae type b & Meningococcal Group C Conjugate VACcine Immunological products and vaccines - Haemophilus influenzae type B vaccine - 14.04
  Hepatitis A VACcine Immunological products and vaccines - Hepatitis A vaccine - 14.04
  Hepatitis A VACcine with Hepatitis B VACcine  (Twinrix®) Immunological products and vaccines - Hepatitis A vaccine - 14.04
  Hepatitis B VACcine Immunological products and vaccines - Hepatitis B vaccine - 14.04
  Human papilloma virus (HPV) VACcine Immunological products and vaccines - Human papilloma virus vaccine - 14.04
  Influenza VACcine Immunological products and vaccines - Influenza vaccine - 14.04
  IVACaftor Respiratory system - Mucolytics - 03.07
  Japanese Encephalitis VACcine  (Ixiaro®) Immunological products and vaccines - Vaccines and antisera - 14.04
  LevobupiVACaine  (Chirocaine®) Anaesthesia - Levobupivacaine - 15.02
  Controlled Drug LevobupiVACaine with Fentanyl Anaesthesia - Opioid analgesics - 15.01.04.03
  Liposomal BupiVACaine  (Exparel® ) Anaesthesia - Bupivacaine - 15.02
  Lumacaftor and IVACaftor  (Orkambi®) Respiratory system - Mucolytics - 03.07
  MaVACamten  (Camzyos®) Cardiovascular system - Miscellaneous - 02.16
  Measles, Mumps and Rubella VACcine, Live (MMR) Immunological products and vaccines - Measles, Mumps and Rubella (MMR) vaccine - 14.04
  MepiVACaine Anaesthesia - Other local anaesthetics - 15.02
  MepiVACaine IV Anaesthesia - Other local anaesthetics - 15.02
  MiVACurium  (MiVACron®) Anaesthesia - Non-depolarising muscle relaxants - 15.01.05
  Pneumococcal polysaccharide conjugate VACcine Immunological products and vaccines - Pneumococcal vaccines - 14.04
  Poliomyelitis VACcine Inactivated (Salk)
(Inactivated poliomyelitis VACcine (IPV)) 		Immunological products and vaccines - Poliomyelitis vaccines - 14.04
  Poliomyelitis VACcine Live (oral) Immunological products and vaccines - Poliomyelitis vaccines - 14.04
  Rabies VACcine Immunological products and vaccines - Rabies vaccine - 14.04
  RopiVACaine Hydrochloride Anaesthesia - Ropivacaine - 15.02
  Rotavirus VACcine  (Rotarix®) Immunological products and vaccines - Rotavirus vaccine - 14.04
  Tetanus VACcine  Immunological products and vaccines - Tetanus vaccines - 14.04
  Tezacaftor and iVACaftor  (Symkevi®) Respiratory system - Mucolytics - 03.07
  Tezacaftor with iVACaftor and elexacaftor  (Kaftrio®) Respiratory system - Mucolytics - 03.07
  Tezacaftor with vanzacaftor and deutiVACaftor  (Alyftrek®) Respiratory system - Mucolytics - 03.07
  Tick-borne encephalitis VACcine Immunological products and vaccines - Tick-borne encephalitis vaccine - 14.04
  Typhoid VACcine Immunological products and vaccines - Typhoid vaccines - 14.04
  Varicella Zoster VACcine  (Zostavax®) Immunological products and vaccines - Varicella-zoster vaccine - 14.04
  Varicella-zoster VACcine Immunological products and vaccines - Varicella-zoster vaccine - 14.04
  Yellow fever VACcine (Live) Immunological products and vaccines - Yellow fever vaccine - 14.04
  Cytotoxic Drug Atezolizumab Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Bendamustine Malignant disease and immunosuppression - Alkylating drugs - 08.01.01
  Calcium Carbonate and Colecalciferol Nutrition and blood - Vitamin D - 09.06.04
  House dust mite allergen immunotherapy  (Acarizax®) Respiratory system - Allergen Immunotherapy - 03.04.02
  Methoxyflurane  (Penthrox®) Anaesthesia - Inhalational anaesthetics - 15.01.02
  Cytotoxic Drug Olaparib  (Lynparza®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Pembrolizumab  (Keytruda®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Triptorelin Injection Endocrine system - Gender dysphoria - 06.04.04
  Whitmore cocktail Obstetrics, Gynaecology, and urinary-tract disorders - Bladder instillations and urological surgery - 07.04.04
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis (03.07)
link in drug section Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis (03.07)
link in drug section Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis (03.07)
link in drug section Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis (03.07)
link in drug section MHRA Drug Safety Update (April 2019): Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older (14.04)
link in drug section MHRA Drug Safety Update (Feb 2022): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on liver function testing (03.07)
link in drug section MHRA Drug Safety Update (Feb 2022): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on liver function testing (03.07)
link in drug section MHRA Drug Safety Update (January 2011): Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (08.01.05)
link in drug section MHRA Drug Safety Update (January 2011): Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (08.01.05)
link in drug section MHRA Drug Safety Update (July 2017): Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation (08.01.01)
link in drug section MHRA Drug Safety Update (March 2021): Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML) (08.01.01)
link in drug section MHRA Drug Safety Update (Nov 2019): Yellow fever vaccine: stronger precautions in people with weakened immunity and in those aged 60 years or older (14.04)
link in drug section MHRA Drug Safety Update (Nov 2021): Yellow fever vaccine (Stamaril): new pre-vaccination checklist (14.04)
link in drug section MHRA Drug Safety Updates: COVID-19 Vaccines (14.04)
link in subsection MHRA Drug Safety Updates: COVID-19 Vaccines (14.04)
link in drug section MHRA: Kaftrio▼ (Ivacaftor, tezacaftor, elexacaftor): risk of psychological side effects (03.07)
link in drug section NICE TA1008 : Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (08.01.03)
link in drug section NICE TA1022: Bevacizumab gamma for treating wet age-related macular degeneration (11.08.02)
link in drug section NICE TA1085: Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over (03.07)
link in drug section NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (08.01.05)
link in drug section NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab (08.01.05)
link in drug section NICE TA353: Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (08.01.05)
link in drug section NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (08.01.05)
link in drug section NICE TA907: Deucravacitinib for treating moderate to severe plaque psoriasis (13.05.03)
link in drug section NICE TA913: Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (02.16)
link in drug section NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (08.01.05)
link in drug section NICE TA946: Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (08.01.05)
link in drug section NICE TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (03.07)
link in drug section SPS COVID-19 vaccine resources (14.04)
link in drug section TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (03.07)
link in drug section TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (03.07)

SubSection Titles / notes  
Anthrax VACcine - (14.04)
BCG VACcines - (14.04)
BeVACizumab - (08.01.05)
BupiVACaine - (15.02)
Cholera VACcine - (14.04)
COVID-19 VACcine - (14.04)
Diphtheria VACcines - (14.04)
Haemophilus influenzae type B VACcine - (14.04)
Hepatitis A VACcine - (14.04)
Hepatitis B VACcine - (14.04)
Human papilloma virus VACcine - (14.04)
Influenza VACcine - (14.04)
International travel - (14.06)
LevobupiVACaine - (15.02)
Measles VACcine - (14.04)
Measles, Mumps and Rubella (MMR) VACcine - (14.04)
Meningococcal VACcines - (14.04)
MepiVACaine - (15.02)
Mumps VACcine - (14.04)
Pertussis VACcine - (14.04)
Pneumococcal VACcines - (14.04)
Poliomyelitis VACcines - (14.04)
Rabies VACcine - (14.04)
RopiVACaine - (15.02)
Rotavirus VACcine - (14.04)
Rubella VACcine - (14.04)
Smallpox VACcine - (14.04)
Tetanus VACcines - (14.04)
Tick-borne encephalitis VACcine - (14.04)
Typhoid VACcines - (14.04)
VACcines and antisera - (14.04)
VACuum assisted closure products - (18.06.01)
Varicella-zoster VACcine - (14.04)
Yellow fever VACcine - (14.04)

 
netFormulary